Fentanyl's Extreme Daily Doses Expose Fatal Gaps in MOUD Protocols and Overdose Surveillance

A 2026 modeling study in Drug and Alcohol Dependence quantified illicit fentanyl intake among 47 Los Angeles users at an average 8,887 morphine milligram equivalents (MME) daily—roughly 60 times the CDC's lethal threshold for opioid-naïve individuals. Drawing on purity testing of over 500 samples from September 2023 to January 2026 plus self-reported consumption, the observational analysis reveals doses equivalent to hundreds of hospital fentanyl vials, far exceeding protocols designed for heroin-era tolerance. This non-randomized modeling approach carries inherent limitations from small survey size and regional focus, with no declared conflicts but reliance on Drug Checking Los Angeles data potentially introducing selection bias. Standard overdose reporting misses these tolerance patterns because it tracks fatalities rather than chronic high-MME exposure; synthesizing with CDC surveillance data (2023-2025) shows fentanyl purity variability (often 5-20%) amplifies unpredictable withdrawal severity, undermining buprenorphine induction success rates observed in earlier heroin-dominant cohorts (e.g., a 2022 observational study in Addiction, n=1,200). A related 2024 RCT in JAMA Network Open (n=312) confirmed MOUD reduces mortality but highlighted 40% higher dropout when baseline tolerance exceeds 2,000 MME, a threshold now routinely surpassed. The original coverage understates national scalability, ignoring how cheap synthetic production enables consistent high dosing unlike variable heroin supply chains. Public health must pivot from static dosing guidelines to dynamic, adjuvant-supported withdrawal management informed by real-time drug checking.